John M. Jumper, the 2024 Nobel Prize in Chemistry winner who led the AlphaFold project at Google DeepMind, announced his departure from the company to join rival AI lab Anthropic. The move, confirmed on June 19, marks one of the highest-profile talent transfers in the escalating competition among frontier AI labs.
Jumper announced the news on X, thanking DeepMind CEO Demis Hassabis for “taking a real chance letting me lead the AlphaFold team just six months after finishing my PhD.” He added that “the entire GDM team taught me so much about how to do great science.”
Jumper shared the 2024 Nobel Prize in Chemistry with Hassabis for AlphaFold, the AI system that predicts three-dimensional protein structures from amino acid sequences. The model solved a 50-year grand challenge in biology and has been used by more than 2 million researchers worldwide, accelerating work on drug discovery, enzyme design, and disease understanding.
At Anthropic, Jumper is expected to lead scientific AI research, bringing protein-folding expertise to a company that has focused primarily on general-purpose language models. The hire strengthens Anthropic’s bench in the life sciences at a time when the company is also expanding into enterprise coding tools and agentic systems.
Brains drain from DeepMind
Jumper’s departure comes in the same week that Noam Shazeer, co-founder of Character AI and a former Google researcher, left DeepMind for OpenAI. The back-to-back exits signal a worrisome talent retention problem for DeepMind as its two biggest rivals poach senior researchers.
Bloomberg reported that Jumper had been a key member of Google’s AI coding tools development team, a business where Google has struggled to compete. The departures raise questions about DeepMind’s ability to hold onto its top talent as the financial incentives and research autonomy offered by well-funded startups grow increasingly attractive.
AlphaFold’s legacy
AlphaFold itself continues to reverberate through biology. The system’s AlphaFold Database now contains over 200 million predicted protein structures, covering virtually every known protein on Earth. In 2025, DeepMind spun out Isomorphic Labs as a separate drug-discovery company applying AlphaFold’s principles to small-molecule therapeutics.
Jumper’s transition to Anthropic does not affect the existing AlphaFold database or the Isomorphic Labs spinout, both of which remain under DeepMind and Alphabet.